News Releases

July 2019

July 22, 2019 7/22/2019 Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn's Disease

May 2019

May 19, 2019 5/19/2019 New Exploratory Data from VARSITY Study of Vedolizumab Presented at 2019 Digestive Disease Week

May 19, 2019 5/19/2019 New Exploratory Data from VARSITY Study of Vedolizumab Presented at DDW

May 17, 2019 5/17/2019 U.S. FDA Approves GATTEX® (teduglutide) for Children 1 Year of Age and Older With Short Bowel Syndrome (SBS)

May 16, 2019 5/16/2019 Takeda to Highlight Compelling New Data and Portfolio Advances for Gastrointestinal (GI) Diseases at DDW 2019

May 15, 2019 5/15/2019 Takeda to host two panel discussions at American Psychiatric Association Meeting

May 15, 2019 5/15/2019 Takeda and Frazier Healthcare Partners Announce Collaboration to Launch Phathom Pharmaceuticals

May 9, 2019 5/9/2019 U.S. Food & Drug Administration Accepts Takeda’s Biologics License Application for a Subcutaneous Formulation of Vedolizumab (Entyvio®)